CoChat

The use of novel agents in the treatment of relapsed and refractory multiple myeloma

Open access
Laubach, J P, Mahindra, A, Mitsiades, C S, Schlossman, R L, Munshi, N C, Ghobrial, I M, Carreau, N, Hideshima, T, Anderson, K C, Richardson, P G · 2009 · Leukemia
Cited by 78

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Although outcomes for patients with multiple myeloma (MM) have improved over the past decade, the disease remains incurable and even patients who respond well to induction therapy ultimately relapse and require additional treatment. Conventional chemotherapy and high-dose therapy with stem cell transplantation (SCT) have historically been utilized in the management of relapsed MM, but in recent years the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, as well as the proteasome inhibitor bortezomib, have assumed a primary role in this setting. This review focuses on the role of thalidomide, lenalidomide and bortezomib in relapsed and refractory MM, with additional discussion dedicated to emerging drugs in relapsed MM that may prove beneficial to patients with this disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2009.179

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 78

Metadata

Authors
Laubach, J. P., Mahindra, A., Mitsiades, C. S., Schlossman, R. L., Munshi, N. C., Ghobrial, I. M., Carreau, N., Hideshima, T., Anderson, K. C., & Richardson, P. G.
Venue
Leukemia
Published
2009-09-10
Volume
23
Issue
12
Pages
2222-2232
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W1974798389
Cited by
78
References
12
FWCI
8.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The use of novel agents in the treatment of relapsed and refractory multiple myeloma. https://app.cochat.ai/papers/10.1038/leu.2009.179
The paper
Laubach, J. P., Mahindra, A., Mitsiades, C. S., Schlossman, R. L., Munshi, N. C., Ghobrial, I. M., Carreau, N., Hideshima, T., Anderson, K. C., & Richardson, P. G. (2009). The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia. https://doi.org/10.1038/leu.2009.179

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.